1-12 of 12
Steven D. Gore
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure

Amer M. Zeidan, Hanna A. Knaus, Tara M. Robinson, Andrea M.H. Towlerton, Edus H. Warren, Joshua F. Zeidner, Amanda L. Blackford, Amy S. Duffield, David Rizzieri, Mark G. Frattini, Yair M. Levy, Mark A. Schroeder, Anna Ferguson, Katherine E. Sheldon, Amy E. DeZern, Ivana Gojo, Steven D. Gore, Howard Streicher, Leo Luznik, B. Douglas Smith
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15): 3519–3527.
https://doi.org/10.1158/1078-0432.CCR-17-3763
Published: 31 July 2018
View article titled, A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure
Open the PDF for A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia

Keith W. Pratz, Michelle A. Rudek, Ivana Gojo, Mark R. Litzow, Michael A. McDevitt, Jiuping Ji, Larry M. Karnitz, James G. Herman, Robert J. Kinders, B. Douglas Smith, Steven D. Gore, Hetty E. Carraway, Margaret M. Showel, Douglas E. Gladstone, Mark J. Levis, Hua-Ling Tsai, Gary Rosner, Alice Chen, Scott H. Kaufmann, Judith E. Karp
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (4): 899–907.
https://doi.org/10.1158/1078-0432.CCR-16-1274
Published: 14 February 2017
View article titled, A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
Open the PDF for A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia

Ivana Gojo, Jan H. Beumer, Keith W. Pratz, Michael A. McDevitt, Maria R. Baer, Amanda L. Blackford, B. Douglas Smith, Steven D. Gore, Hetty E. Carraway, Margaret M. Showel, Mark J. Levis, Amy E. Dezern, Douglas E. Gladstone, Jiuping Jay Ji, Lihua Wang, Robert J. Kinders, Marie Pouquet, Ismail Ali-Walbi, Michelle A. Rudek, Weijie Poh, James G. Herman, Larry M. Karnitz, Scott H. Kaufmann, Alice Chen, Judith E. Karp
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (3): 697–706.
https://doi.org/10.1158/1078-0432.CCR-16-0984
Published: 31 January 2017
View article titled, A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
Open the PDF for A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

New Strategies in Acute Promyelocytic Leukemia: Moving to an Entirely Oral, Chemotherapy-Free Upfront Management Approach

Amer M. Zeidan, Steven D. Gore
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (19): 4985–4993.
https://doi.org/10.1158/1078-0432.CCR-13-2725
Published: 30 September 2014
View article titled, New Strategies in Acute Promyelocytic Leukemia: Moving to an Entirely Oral, Chemotherapy-Free Upfront Management Approach
Open the PDF for New Strategies in Acute Promyelocytic Leukemia: Moving to an Entirely Oral, Chemotherapy-Free Upfront Management Approach in another window
Journal Articles

Decitabine Induces Delayed Reactive Oxygen Species (ROS) Accumulation in Leukemia Cells and Induces the Expression of ROS Generating Enzymes

Tamer E. Fandy, Anchalee Jiemjit, Manjusha Thakar, Paulette Rhoden, Lauren Suarez, Steven D. Gore
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (5): 1249–1258.
https://doi.org/10.1158/1078-0432.CCR-13-1453
Published: 02 March 2014
View article titled, Decitabine Induces Delayed Reactive Oxygen Species (ROS) Accumulation in Leukemia Cells and Induces the Expression of ROS Generating Enzymes
Open the PDF for Decitabine Induces Delayed Reactive Oxygen Species (ROS) Accumulation in Leukemia Cells and Induces the Expression of ROS Generating Enzymes in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias

Judith E. Karp, Brian M. Thomas, Jacqueline M. Greer, Christopher Sorge, Steven D. Gore, Keith W. Pratz, B. Douglas Smith, Karen S. Flatten, Kevin Peterson, Paula Schneider, Karen Mackey, Tomoko Freshwater, Mark J. Levis, Michael A. McDevitt, Hetty E. Carraway, Douglas E. Gladstone, Margaret M. Showel, Sabine Loechner, David A. Parry, Jo Ann Horowitz, Randi Isaacs, Scott H. Kaufmann
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (24): 6723–6731.
https://doi.org/10.1158/1078-0432.CCR-12-2442
Published: 16 December 2012
View article titled, Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias
Open the PDF for Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias in another window
Journal Articles

Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features

Judith E. Karp, B. Douglas Smith, Ivana Gojo, Jeffrey E. Lancet, Jacqueline Greer, Maureen Klein, Larry Morris, Mark J. Levis, Steven D. Gore, John J. Wright, Elizabeth Garrett-Mayer
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (10): 3077–3082.
https://doi.org/10.1158/1078-0432.CCR-07-4743
Published: 15 May 2008
View article titled, Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features
Open the PDF for Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features in another window
Journal Articles

Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia

Judith E. Karp, B. Douglas Smith, Mark J. Levis, Steven D. Gore, Jacqueline Greer, Catherine Hattenburg, Janet Briel, Richard J. Jones, John J. Wright, A. Dimitri Colevas
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (15): 4467–4473.
https://doi.org/10.1158/1078-0432.CCR-07-0381
Published: 01 August 2007
View article titled, Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia
Open the PDF for Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia in another window
Journal Articles

Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-β-d-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias

Judith E. Karp, Antonino Passaniti, Ivana Gojo, Scott Kaufmann, Keith Bible, Tushar S. Garimella, Jacqueline Greer, Janet Briel, B. Douglas Smith, Steven D. Gore, Michael L. Tidwell, Douglas D. Ross, John J. Wright, A. Dimitrios Colevas, Kenneth S. Bauer
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (23): 8403–8412.
https://doi.org/10.1158/1078-0432.CCR-05-1201
Published: 01 December 2005
View article titled, Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-β-<sc>d</sc>-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias
Open the PDF for Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-β-<sc>d</sc>-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias in another window
Journal Articles

State of the Translational Science: Summary of Baltimore Workshop on Gene Re-expression As a Therapeutic Target in Cancer January 2003

Arthur Zelent, Samuel Waxman, Michael Carducci, John Wright, James Zweibel, Steven D. Gore
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (14): 4622–4629.
https://doi.org/10.1158/1078-0432.CCR-1219-03
Published: 21 July 2004
View article titled, State of the Translational Science: <subtitle>Summary of Baltimore Workshop on Gene Re-expression As a Therapeutic Target in Cancer January 2003</subtitle>
Open the PDF for State of the Translational Science: <subtitle>Summary of Baltimore Workshop on Gene Re-expression As a Therapeutic Target in Cancer January 2003</subtitle> in another window
Journal Articles

Impact of Prolonged Infusions of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia

Steven D. Gore, Li-Jun Weng, William D. Figg, Suoping Zhai, Ross C. Donehower, George Dover, Michael R. Grever, Constance Griffin, Louise B. Grochow, Anita Hawkins, Kathleen Burks, Yelena Zabelena, Carole B. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (4): 963–970.
Published: 01 April 2002
View article titled, Impact of Prolonged Infusions of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia
Open the PDF for Impact of Prolonged Infusions of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia in another window
Journal Articles

Impact of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia

Steven D. Gore, Li-Jun Weng, Suoping Zhai, William D. Figg, Ross C. Donehower, George J. Dover, Michael Grever, Constance A. Griffin, Louise B. Grochow, Eric K. Rowinsky, Yelena Zabalena, Anita L. Hawkins, Kathleen Burks, Carole B. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (8): 2330–2339.
Published: 01 August 2001
View article titled, Impact of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia
Open the PDF for Impact of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia in another window